The Tvardi Therapeutics, Inc. (NASDAQ: TVRD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tvardi’s filings describe it as a Delaware corporation and a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need.
Through documents such as Form 8-K current reports, investors can review Tvardi’s announcements regarding financial results, business updates, executive and director changes, compensation arrangements, and key clinical and corporate events. Recent 8-K filings have covered quarterly results, updates on preliminary data from the REVERT IPF Phase 2 trial of TTI-101 in idiopathic pulmonary fibrosis, the availability of updated corporate presentations, and the adoption of a severance and change in control plan and retention equity awards for certain employees.
Registration statements on Form S-1/A offer additional detail on Tvardi’s business following its merger with Legacy Tvardi, the change of name from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc., and the commencement of trading on The Nasdaq Capital Market under the symbol TVRD. These filings also outline the company’s status as a smaller reporting company and its focus on STAT3-targeted clinical programs, including TTI-101 and TTI-109.
On Stock Titan, Tvardi’s SEC filings are updated as new documents are posted to EDGAR, and AI-powered summaries can help explain the key points in lengthy filings such as registration statements and current reports. Users can quickly identify items related to clinical trial disclosures, capital structure, compensation plans, and other material events, and can also monitor how Tvardi describes the progress and risks associated with its STAT3 inhibitor programs over time.
Tvardi Therapeutics, Inc. files a Post-Effective Amendment converting its prior Form S-1 into a Form S-3 to register the resale of up to 593,758 shares of common stock held by selling stockholders pursuant to the Merger Agreement.
The prospectus states these are resale shares by selling stockholders and that the company will receive no proceeds from sales. The prospectus also discloses 9,381,344 shares outstanding as of May 1, 2026 and a Nasdaq last reported sale price of $4.21 on May 7, 2026.
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing oral STAT3 inhibitors TTI-101 and TTI-109 for inflammatory and proliferative diseases. TTI-101 is in Phase 1b/2 for hepatocellular carcinoma, and TTI-109 is in a Phase 1 healthy volunteer trial.
For the three months ended March 31, 2026, Tvardi reported a net loss of $6.8 million, compared with $9.6 million a year earlier, driven by $4.9 million in research and development and $2.1 million in general and administrative expenses. The company had $19.9 million in cash and cash equivalents and $5.1 million in short-term investments, with an accumulated deficit of $117.3 million.
Management states that these resources are not sufficient to fund operations for at least one year and concludes that substantial doubt exists about Tvardi’s ability to continue as a going concern. On May 1, 2026, Tvardi filed a Form S-3 shelf registration for up to $200.0 million of securities, including an at-the-market facility of up to $12.5 million in common stock, which will only be available after SEC effectiveness.
Tvardi Therapeutics, Inc. reported first quarter 2026 results and highlighted upcoming clinical milestones. Research and development expenses rose to $4.9 million from $3.1 million a year earlier, mainly from higher costs for next-generation STAT3 inhibitor TTI-109, partly offset by lower spending on TTI-101.
General and administrative expenses increased to $2.1 million from $1.2 million, driven by higher personnel, stock-based compensation and public-company costs. Net loss narrowed to $6.8 million from $9.6 million, with net loss per share improving to $(0.73) from $(3.72).
Cash, cash equivalents and short-term investments were $25.0 million as of March 31, 2026, down from $30.8 million at year-end 2025. Tvardi expects this cash to fund operations through key clinical readouts and into the fourth quarter of 2026, including June topline data for TTI-109 and second-half 2026 topline data from the Phase 2 REVERT LIVER CANCER trial of TTI-101.
Tvardi Therapeutics, Inc. is registering a shelf to offer up to $200,000,000 of common stock, preferred stock, debt securities and/or warrants.
The filing also includes a Sales Agreement prospectus authorizing offers of up to $12,500,000 of common stock under a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC. The prospectus states the company’s common stock trades on Nasdaq under the symbol TVRD and reports a last quoted sale price of $3.15 on April 30, 2026.
Tvardi Therapeutics, Inc. has issued its proxy materials for the 2026 virtual annual meeting of stockholders, to be held on June 9, 2026 at 12:00 p.m. Eastern via webcast. Holders of 9,381,344 shares of common stock outstanding as of April 14, 2026 are entitled to vote.
Stockholders will vote on electing three Class II directors to terms ending in 2029, a non-binding advisory “say-on-pay” vote on executive compensation, an advisory vote on how often to hold future say-on-pay votes, and ratification of the independent registered public accounting firm.
The proxy describes Tvardi’s 2025 reverse merger with Cara Therapeutics, a 1‑for‑3 reverse stock split, an increase in authorized common shares to 150,000,000, and Nasdaq listing under the symbol TVRD. It outlines board independence, committee structure, director pay, 2025 executive pay, annual bonus targets, new stock option grants, and a severance and change-in-control plan covering senior executives.
Tvardi Therapeutics, Inc. filed a Post-Effective Amendment No. 1 to its Form S-1 on April 1, 2026 to include the consent of Deloitte & Touche LLP to its report dated March 31, 2026 relating to financial statements in the Annual Report on Form 10-K for the year ended December 31, 2025. The amendment is an exhibit-only filing under Rule 462(d) and does not change the prospectus or the balance of Part II of the Registration Statement.
Tvardi Therapeutics (TVRD) files a prospectus supplement registering the resale of up to 2,084,117 shares of common stock by selling stockholders pursuant to the Merger Agreement. The supplement attaches portions of the Form 10-K for the fiscal year ended December 31, 2025, and updates disclosure with clinical and corporate information.
The 10-K describes Tvardi’s pipeline focused on direct STAT3 inhibitors (TTI-101 and prodrug TTI-109), clinical programs in IPF and HCC, Phase 1 and Phase 2 trial details, IND acceptance for TTI-109, certain preclinical findings, patent and license arrangements with Baylor College of Medicine, and corporate reorganizations following the Merger. Shares outstanding were 9,381,344 as of March 26, 2026.